Connect with us

Business

Present Yourself as a ‘No Brainer’ to Hire

Published

 on

A few jobs back, HR had scheduled four interviews, throughout my day, for a position I had open. The first interview went “okay.” The second candidate, however, impressed me so much I hired him on the spot. I instructed HR to cancel the remaining two interviews.

 

The second candidate did something I rarely see—they presented themselves as a ‘no brainer’ to hire.

 

How?

 

  • Their resume was result-oriented (Not a list of opinions — “I’m a team player,” “detail-oriented,” “hard-working,” etc.).
  • They dressed as if they were already employed with my company. (In this case, a global multi-brand tour operator.)
  • They clearly articulated their value.
  • They told me several STAR (Situation. Task. Action. Results.) stories I could envision and relate to.

 

If your resume (skills and experience) impressed the employer, and after reading your LinkedIn profile to determine if you’re interview-worthy, you’ll be invited to an interview—the first most likely being via Zoom or Skype.

 

Impressing someone on paper and via your LinkedIn profile has its challenges, especially since you’re competing against many other candidates just as qualified as you. However, where the rubber meets the road is when you’re sitting face-to-face with the hiring manager.

 

Presenting yourself in a way your interviewer can envision you fitting with the company’s culture and the current team, as well as gives them confidence you’ll hit the ground running, will substantially increase your odds of receiving a nod of approval.

 

Regardless of whether you’re interviewing via video, sitting in a boardroom, a coffee shop or the interviewer’s office, focus on the following:

 

  1. Your attire
  2. Your body language
  3. Articulating how you meet the employer’s needs and will solve the problems the position exists to solve
  4. Being mindful of your interviewer’s time.

 

 

As I’ve mentioned in a previous column, being deemed “a fit” supersedes your experience and qualifications. Your image is paramount in giving the impression you’re “one of them.”

 

Make sure your attire is in line with the company culture. Obviously, this will differ from company to company, as well as between industries. If you’re interviewing for a position in a bank or insurance company, formal attire, even in 2021, is appropriate, such as a business suit, shirt, and tie. On the opposite end of the spectrum, casual clothing, even jeans and sneakers, can be acceptable if you’re interviewing with a design studio or tech start-up. The key is to dress as if you already work for the employer.

 

  1. Body language.

 

Your body language, along with your words, greatly influences the first impressions someone has about you.

 

If you’re seated, say in the reception area, stand to greet your interviewer. Firmly shake your interviewer’s hand, or each member of your interview panel, while maintaining a broad smile and steady eye contact. Say something along the lines of, “Nice to meet you, Alice.” Remember your interviewer’s name and use it naturally throughout your interview. Maintain eye contact during the interview. This shows your interviewer(s) you’re engaged in the conversation. Speak in a clear and audible voice. Your posture can portray you as arrogant, so be conscious of the way you sit or stand. During the interview, display a natural body language with relaxed shoulders and open arms by your side.

 

  1. Articulate how you meet the employer’s needs. 

 

This is where you solidify, you’re a ‘no brainer’ to hire. 

 

If you’re interviewing with the person you’d be reporting to, keep this piece of human psychology in mind: A person is more likely to want to build a relationship with you if you understand their situation, problems, and goals.

 

Start with the job description. Now that you’ve landed an interview, refer to the job description, paying close attention to job qualifications and duties.

 

Have STAR stories ready regarding specific situations in which you used each of these skills. Try to keep your STARs short and vivid. The best STAR ever said to me: “I sold Corvettes in Las Vegas.” (Yes, I hired the person.)

 

  1. Be mindful of the time.

 

Always be punctual for your scheduled interview time! Being punctual is a sign of being a professional, as well as respect for the other person. Stick within the time frame your interview was scheduled for. (usually 45 minutes to 1 hour)

 

In 2021 employers are looking for candidates who’ll mesh with their workplace culture. Showing you belong will go a long way in making yourself a ‘no brainer’ to hire.

______________________________________________________________

 

Nick Kossovan, a well-seasoned veteran of the corporate landscape, offers advice on searching for a job. You can send him your questions at artoffindingwork@gmail.com.

 

 

Business

Tesla stock surges as Hertz orders 100,000 electric cars – Aljazeera.com

Published

 on


[unable to retrieve full-text content]

  1. Tesla stock surges as Hertz orders 100,000 electric cars  Aljazeera.com
  2. Hertz to buy 100,000 Teslas for its rental fleet by next year  CBC.ca
  3. Tesla soars on Hertz deal  CNBC Television
  4. The Hertz-Tesla Deal Will Help Normalize Electric Cars  Bloomberg
  5. Elon Musk Makes Tesla, Hertz and Bitcoin Memes Go Up  Bloomberg
  6. View Full coverage on Google News



Source link

Continue Reading

Business

UBS logs surprise 9% rise in Q3 net profit

Published

 on

UBS posted a 9% rise in third-quarter net profit on Tuesday, as continued trading helped the world’s largest wealth manager to its best quarterly profit since 2015.

Its third-quarter net profit of $2.279 billion far outpaced a median estimate of $1.596 billion from a poll of 23 analysts compiled by Switzerland’s largest bank.

“Our business momentum, our focus on fueling growth, on disciplined execution and on delivering our full ecosystem to clients – all of this led to another strong quarter across all of our business divisions and regions,” Chief Executive Ralph Hamers said in a statement.

In each of the last four quarters, UBS saw double-digit percent gains in net profit as buoyant markets helped it generate higher earnings off of managing money for the rich.

From July through September, favourable market conditions, and higher lending and trading amongst its wealthy clientele, unexpectedly helped raise earnings over the bumper levels reported in the third quarter of last year.

 

(Reporting by Oliver Hirt and Brenna Hughes Neghaiwi; Editing by Michael Shields and Edwina Gibbs)

Continue Reading

Business

Analysis: Capitol Hill drug pricing reform opponents among the biggest beneficiaries of pharma funds

Published

 on

Democratic Party lawmakers holding up proposed drug pricing reforms are among the largest beneficiaries of the pharmaceutical industry’s push to stave off price cuts, a Reuters analysis of public lobbying and campaign data shows.

The industry, which traditionally gives more to Republicans, channeled around 60% of donated campaign funds to Democrats this year. It has spent over $177 million on lobbying and campaign donations in 2021.

Nonprofit political action committees (PACs) run by Pfizer Inc and Amgen Inc and the Pharmaceutical Research and Manufacturers of America (PhRMA) were among the biggest donors, according to political spending data from OpenSecrets, formerly the Center for Responsive Politics.

Drugmakers are seeking to block laws that would give the U.S. government authority to negotiate prices for prescription medicines. Current U.S. law bars the government’s Medicare health insurance program from negotiating drug prices directly.

Many of the Democrats opposing an ambitious drug reduction bill proposed in the House of Representatives are among some of the biggest recipients of drug manufacturer lobbying funds.

They include Senators Kyrsten Sinema of Arizona, Robert Menendez of New Jersey, and Representative Scott Peters of California, OpenSecrets data covering industry donations through September of 2021 shows. In all, they have received around $1 million in pharmaceutical and health product industry donations this year.

A spokesperson for Sinema did not respond to a request for comment on the funds she has received but said the Senator supports making drugs as cheap as possible for patients.

Menendez and Peters said the donations did not influence their views. All three said they are opposed to The Lower Drug Costs Now Act, which is sponsored by Democrats in the House of Representatives and also known as H.R.3.

Menendez and Peters have advocated for alternative scaled-back drug pricing reforms that would still allow Medicare to negotiate drug prices but would lead to significantly smaller savings.

Congressman Frank Pallone of New Jersey, who is also one of the top recipients of drugmaker donations, voted in favor of H.R.3.

Sinema, who campaigned in 2018 on cutting drug prices, told the White House she opposes allowing Medicare to negotiate them. She received about $466,000 from the industry in 2021, according to OpenSecrets data.

Peters was the top recipient of pharmaceutical industry funds in the House this year at nearly $99,550, according to OpenSecrets data. A spokesperson said Peters was not influenced by lobbying money and opposed the proposed law to protect pharmaceutical industry jobs and innovation.

Drugmakers say the Democrats’ proposed drug price overhaul would undermine their ability to develop new medicines, an argument they have used whenever price cuts are discussed by politicians regardless of political party.

“Patients face a future with less hope under Congress’ current drug pricing plan,” PhRMA Chief Executive Steve Ubl said in an August statement in reference to the proposed law. PhRMA declined to comment on donating to key Democratic opponents of the bill.

The United States is an outlier as most other developed nations do negotiate drug prices with manufacturers.

Amgen did not immediately respond to requests for comment on its donations and Pfizer declined to comment.

PROSPECTS FOR REFORM

President Joe Biden has vowed to cut medicine costs, in part by allowing the federal government to negotiate drug payments by Medicare, which covers Americans aged 65 and older.

But prospects for major drug pricing reforms have stalled in recent weeks amid opposition from centrist Democrats including Sinema and Peters. Negotiations are ongoing, eight Democratic staffers said.

The lawmakers’ resistance comes as 83% of Americans support allowing Medicare to negotiate medicine costs, according to a Kaiser Family Foundation poll. The United States spends more than twice as much per person on drugs as other wealthy economies, about $1,500, for a total of around $350 billion in 2019.

“Members of Congress don’t always mirror the views of the public and the pharmaceutical industry is a powerful lobbying force,” said Larry Levitt, a health economist at Kaiser.

The healthcare industry is the second largest industry lobbying group in the United States behind the finance sector. It donated more than $600 million to politicians ahead of the 2020 elections.

The pharmaceutical industry has spent hundreds of millions of dollars per year to sway federal and state policy. But current Democratic leadership has the industry concerned major reforms could actually be enacted and is working harder to offer alternatives such as reducing insurance co-pays, one industry source said. “It’s been sort of a mad scramble.”

Corporations in the United States are not permitted to make direct contributions to candidates but can give money through PACs. Most corporate PACs, including Pfizer’s and Amgen’s, are run by company managers and employees.

Democrats and some drug price experts say the Lower Drug Costs Now Act could save U.S. taxpayers and consumers billions annually with relatively minor impact on innovation.

A House Oversight and Reform Committee report showed that top drugmakers have spent around $50 billion more on share buybacks and dividends than research and development between 2016 and 2020.

Lovisa Gustafsson, a healthcare policy analyst at the Commonwealth Fund, a non-profit healthcare advocacy group, said, “There are other ways that we can incentivize innovation, aside from just paying huge margins for pharmaceutical companies.”

 

(Reporting by Ahmed Aboulenein in Washington and Carl O’Donnell in New York; Editing by Caroline Humer and Bill Berkrot)

Continue Reading

Trending